Exact Mass: 481.1631
Exact Mass Matches: 481.1631
Found 500 metabolites which its exact mass value is equals to given mass value 481.1631
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Talampicillin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08557
Pranlukast
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent
Rosuvastatin
Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Pranlukast
Pranlukast is only found in individuals that have used or taken this drug. It is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
Acebilustat
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
(3S)-3-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]-6-fluoro-4,5-dioxohexanoic acid
Benzyloxycarbonylvalyl-alanyl-aspartyl Fluoromethyl Ketone
Talampicillin
2,3-di(acetyloxy)-4-anilino-1-[1,2-di(acetyloxy)ethyl]-4-oxobutyl acetate
(1E)-5-methoxy-6-hydroxycinnamenyl-(1->6)-5,6-dihydrosanguinarine|maclekarpine E
(4Z)-5-{6-O-[(2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]-beta-glucopyranosylsulfanyl}pent-4-enenitrile
Rosuvastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 2802
Ala Cys Cys Trp
Ala Cys Trp Cys
Ala Asp Asn Tyr
Ala Asp Tyr Asn
Ala Phe Met Asn
Ala Phe Asn Met
Ala Met Phe Asn
Ala Met Asn Phe
Ala Asn Asp Tyr
Ala Asn Phe Met
Ala Asn Met Phe
Ala Asn Tyr Asp
Ala Trp Cys Cys
Ala Tyr Asp Asn
Ala Tyr Asn Asp
Cys Ala Cys Trp
Cys Ala Trp Cys
Cys Cys Ala Trp
Cys Cys Glu Lys
Cys Cys Glu Gln
Cys Cys Lys Glu
Cys Cys Gln Glu
Cys Cys Arg Thr
Cys Cys Thr Arg
Cys Cys Trp Ala
Cys Asp Met Asn
Cys Asp Asn Met
Cys Glu Cys Lys
Cys Glu Cys Gln
Cys Glu Lys Cys
Cys Glu Gln Cys
Cys Phe Asn Val
Cys Phe Val Asn
Cys Lys Cys Glu
Cys Lys Glu Cys
Cys Lys Met Thr
Cys Lys Thr Met
Cys Met Asp Asn
Cys Met Lys Thr
Cys Met Asn Asp
Cys Met Gln Thr
Cys Met Thr Lys
Cys Met Thr Gln
Cys Asn Asp Met
Cys Asn Phe Val
Cys Asn Met Asp
Cys Asn Val Phe
Cys Gln Cys Glu
Cys Gln Glu Cys
Cys Gln Met Thr
Cys Gln Thr Met
Cys Arg Cys Thr
Cys Arg Thr Cys
Cys Ser Ser Trp
Cys Ser Trp Ser
Cys Thr Cys Arg
Cys Thr Lys Met
Cys Thr Met Lys
Cys Thr Met Gln
Cys Thr Gln Met
Cys Thr Arg Cys
Cys Val Phe Asn
Cys Val Asn Phe
Cys Trp Ala Cys
Cys Trp Cys Ala
Cys Trp Ser Ser
Asp Ala Asn Tyr
Asp Ala Tyr Asn
Asp Cys Met Asn
Asp Cys Asn Met
Asp Phe Asn Ser
Asp Phe Ser Asn
Asp Gly Gln Tyr
Asp Gly Tyr Gln
Asp His Asn Pro
Asp His Pro Asn
Asp Met Cys Asn
Asp Met Asn Cys
Asp Asn Ala Tyr
Asp Asn Cys Met
Asp Asn Phe Ser
Asp Asn His Pro
Asp Asn Met Cys
Asp Asn Pro His
Asp Asn Ser Phe
Asp Asn Tyr Ala
Asp Pro His Asn
Asp Pro Asn His
Asp Gln Gly Tyr
Asp Gln Tyr Gly
Asp Ser Phe Asn
Asp Ser Asn Phe
Asp Tyr Ala Asn
Asp Tyr Gly Gln
Asp Tyr Asn Ala
Asp Tyr Gln Gly
Glu Cys Cys Lys
Glu Cys Cys Gln
Glu Cys Lys Cys
Glu Cys Gln Cys
Glu Gly Asn Tyr
Glu Gly Tyr Asn
Glu Lys Cys Cys
Glu Asn Gly Tyr
Glu Asn Tyr Gly
Glu Gln Cys Cys
Glu Tyr Gly Asn
Glu Tyr Asn Gly
Phe Ala Met Asn
Phe Ala Asn Met
Phe Cys Asn Val
Phe Cys Val Asn
Phe Asp Asn Ser
Phe Asp Ser Asn
Phe Gly Met Gln
Phe Gly Gln Met
Phe Met Ala Asn
Phe Met Gly Gln
Phe Met Asn Ala
Phe Met Gln Gly
Phe Asn Ala Met
Phe Asn Cys Val
Phe Asn Asp Ser
Phe Asn Met Ala
Phe Asn Ser Asp
Phe Asn Val Cys
Phe Gln Gly Met
Phe Gln Met Gly
Phe Ser Asp Asn
Phe Ser Asn Asp
Phe Val Cys Asn
Phe Val Asn Cys
Gly Asp Gln Tyr
Gly Asp Tyr Gln
Gly Glu Asn Tyr
Gly Glu Tyr Asn
Gly Phe Met Gln
Gly Phe Gln Met
Gly Gly Trp Tyr
Gly Gly Tyr Trp
Gly Met Phe Gln
Gly Met Gln Phe
Gly Asn Glu Tyr
Gly Asn Tyr Glu
Gly Gln Asp Tyr
Gly Gln Phe Met
Gly Gln Met Phe
Gly Gln Tyr Asp
Gly Trp Gly Tyr
Gly Trp Tyr Gly
Gly Tyr Asp Gln
Gly Tyr Glu Asn
Gly Tyr Gly Trp
Gly Tyr Asn Glu
Gly Tyr Gln Asp
Gly Tyr Trp Gly
His Asp Asn Pro
His Asp Pro Asn
His Asn Asp Pro
His Asn Pro Asp
His Pro Asp Asn
His Pro Asn Asp
Lys Cys Cys Glu
Lys Cys Glu Cys
Lys Cys Met Thr
Lys Cys Thr Met
Lys Glu Cys Cys
Lys Met Cys Thr
Lys Met Thr Cys
Lys Thr Cys Met
Lys Thr Met Cys
Met Ala Phe Asn
Met Ala Asn Phe
Met Cys Asp Asn
Met Cys Lys Thr
Met Cys Asn Asp
Met Cys Gln Thr
Met Cys Thr Lys
Met Cys Thr Gln
Met Asp Cys Asn
Met Asp Asn Cys
Met Phe Ala Asn
Met Phe Gly Gln
Met Phe Asn Ala
Met Phe Gln Gly
Met Gly Phe Gln
Met Gly Gln Phe
Met Lys Cys Thr
Met Lys Thr Cys
Met Met Asn Ser
Met Met Ser Asn
Met Asn Ala Phe
Met Asn Cys Asp
Met Asn Asp Cys
Met Asn Phe Ala
Met Asn Met Ser
Met Asn Ser Met
Met Gln Cys Thr
Met Gln Phe Gly
Met Gln Gly Phe
Met Gln Thr Cys
Met Ser Met Asn
Met Ser Asn Met
Met Thr Cys Lys
Met Thr Cys Gln
Met Thr Lys Cys
Met Thr Gln Cys
Asn Ala Asp Tyr
Asn Ala Phe Met
Asn Ala Met Phe
Asn Ala Tyr Asp
Asn Cys Asp Met
Asn Cys Phe Val
Asn Cys Met Asp
Asn Cys Val Phe
Asn Asp Ala Tyr
Asn Asp Cys Met
Asn Asp Phe Ser
Asn Asp His Pro
Asn Asp Met Cys
Asn Asp Pro His
Asn Asp Ser Phe
Asn Asp Tyr Ala
Asn Glu Gly Tyr
Asn Glu Tyr Gly
Asn Phe Ala Met
Asn Phe Cys Val
Asn Phe Asp Ser
Asn Phe Met Ala
Asn Phe Ser Asp
Asn Phe Val Cys
Asn Gly Glu Tyr
Asn Gly Tyr Glu
Asn His Asp Pro
Asn His Pro Asp
Asn Met Ala Phe
Asn Met Cys Asp
Asn Met Asp Cys
Asn Met Phe Ala
Asn Met Met Ser
Asn Met Ser Met
Asn Pro Asp His
Asn Pro His Asp
Asn Ser Asp Phe
Asn Ser Phe Asp
Asn Ser Met Met
Asn Val Cys Phe
Asn Val Phe Cys
Asn Tyr Ala Asp
Asn Tyr Asp Ala
Asn Tyr Glu Gly
Asn Tyr Gly Glu
Pro Asp His Asn
Pro Asp Asn His
Pro His Asp Asn
Pro His Asn Asp
Pro Asn Asp His
Pro Asn His Asp
Gln Cys Cys Glu
Gln Cys Glu Cys
Gln Cys Met Thr
Gln Cys Thr Met
Gln Asp Gly Tyr
Gln Asp Tyr Gly
Gln Glu Cys Cys
Gln Phe Gly Met
Gln Phe Met Gly
Gln Gly Asp Tyr
Gln Gly Phe Met
Gln Gly Met Phe
Gln Gly Tyr Asp
Gln Met Cys Thr
Gln Met Phe Gly
Gln Met Gly Phe
Gln Met Thr Cys
Gln Thr Cys Met
Gln Thr Met Cys
Gln Tyr Asp Gly
Gln Tyr Gly Asp
Arg Cys Cys Thr
Arg Cys Thr Cys
Arg Thr Cys Cys
Ser Cys Ser Trp
Ser Cys Trp Ser
Ser Asp Phe Asn
Ser Asp Asn Phe
Ser Phe Asp Asn
Ser Phe Asn Asp
Ser Met Met Asn
Ser Met Asn Met
Ser Asn Asp Phe
Ser Asn Phe Asp
Ser Asn Met Met
Ser Ser Cys Trp
Ser Ser Trp Cys
Ser Trp Cys Ser
Ser Trp Ser Cys
Thr Cys Cys Arg
Thr Cys Lys Met
Thr Cys Met Gln
Thr Cys Gln Met
Thr Cys Arg Cys
Thr Met Cys Gln
Thr Met Gln Cys
Thr Gln Cys Met
Thr Gln Met Cys
Thr Arg Cys Cys
Val Cys Phe Asn
Val Cys Asn Phe
Val Phe Cys Asn
Val Phe Asn Cys
Val Asn Cys Phe
Val Asn Phe Cys
Trp Ala Cys Cys
Trp Cys Ala Cys
Trp Cys Cys Ala
Trp Cys Ser Ser
Trp Gly Gly Tyr
Trp Gly Tyr Gly
Trp Ser Cys Ser
Trp Ser Ser Cys
Trp Tyr Gly Gly
Tyr Ala Asp Asn
Tyr Ala Asn Asp
Tyr Asp Ala Asn
Tyr Asp Gly Gln
Tyr Asp Asn Ala
Tyr Asp Gln Gly
Tyr Glu Gly Asn
Tyr Glu Asn Gly
Tyr Gly Asp Gln
Tyr Gly Glu Asn
Tyr Gly Gly Trp
Tyr Gly Asn Glu
Tyr Gly Gln Asp
Tyr Gly Trp Gly
Tyr Asn Ala Asp
Tyr Asn Asp Ala
Tyr Asn Glu Gly
Tyr Asn Gly Glu
Tyr Gln Asp Gly
Tyr Gln Gly Asp
Tyr Trp Gly Gly
3-Ethyl-5-methyl-4-(2-chlorophenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Bifeprunox Mesylate
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pKis of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox mesylate is an antipsychotic for the research of schizophrenia[1][2].
methyl 2-[[3-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-hydroxy-1-naphthyl]azo]benzoate
1H-Pyrrolo[2,3-b]pyridine, 1-[(4-Methylphenyl)sulfonyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(2-thiazolyl)-
6-[2-[6-(2-dimethylaminoethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]acetyl]-2,3-dimethoxy-benzoic acid
Acebilustat
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C308 - Immunotherapeutic Agent > C574 - Immunosuppressant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
diethyl 2,6-bis((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
(E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
2-[[4-[(2,6-Dimethyl-4-morpholinyl)sulfonyl]phenyl]-oxomethyl]imino-3,4-dimethyl-5-thiazolecarboxylic acid ethyl ester
(3r,5r,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-
Cefepime conjugate acid
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DE - Fourth-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Cbz-DL-Val-DL-Ala-DL-Asp-AcF
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D009676 - Noxae > D000477 - Alkylating Agents > D000590 - Amino Acid Chloromethyl Ketones D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents
(3S)-3-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]-6-fluoro-4,5-dioxohexanoic acid
[2-[2-[[2-[(4-Amino-4-carboxybutanoyl)amino]-3-(hydroxymethylsulfanyl)propanoyl]amino]acetyl]oxy-3-carboxypropyl]-trimethylazanium
6-[5-[[(5-cyano-4-oxo-6-phenyl-1H-pyrimidin-2-yl)thio]methyl]-2-oxo-1,3-dihydroimidazol-4-yl]-6-oxohexanoic acid ethyl ester
Arg-Thr-Cys-Cys
A tetrapeptide composed of L-arginine, L-threonine and two L-cysteine units joined in sequence by peptide linkages.
N-[2-[(2-furanylmethylamino)-oxomethyl]phenyl]-4-methyl-3-(1-piperidinylsulfonyl)benzamide
6-[4-Methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid
3-(1,3-benzodioxol-5-ylmethyl)-7-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-2-sulfanylidene-1H-quinazolin-4-one
5-methyl-4-[(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-(3-nitrophenyl)methyl]-2-phenyl-1H-pyrazol-3-one
2-[(4-ethoxyphenyl)sulfonylamino]-N-[2-(4-morpholinyl)phenyl]benzamide
N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
(6R,7S,8R)-8-(hydroxymethyl)-7-[4-[2-(3-methoxyphenyl)ethynyl]phenyl]-4-[1-oxo-2-(3-pyridinyl)ethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
[2-[4-(2-Cyclohexylethyl)piperazin-1-yl]-2-oxoethyl] 4-methylsulfonyl-3-nitrobenzoate
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-[[4-[3-(dimethylamino)propyl]-5-pyridin-4-yl-1,2,4-triazol-3-yl]thio]acetamide
3-(4-chlorophenyl)-1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
(2S,3S,3aR,9bR)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
3-(4-chlorophenyl)-1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
3-(4-chlorophenyl)-1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
(1S,9R,10R,11R)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
2,2,2-trifluoro-N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
1-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(2-methylphenyl)sulfonylamino]ethyl]-3-oxanyl]urea
3-(4-chlorophenyl)-1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
3-(4-chlorophenyl)-1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
(1R,9S,10S,11S)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-[2-(3-methoxyphenyl)ethynyl]phenyl]-4-[1-oxo-2-(3-pyridinyl)ethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[[(2R,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-N-methyl-2-thiophenesulfonamide
N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
2,2,2-trifluoro-N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
2,2,2-trifluoro-N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide
1-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
1-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(4-methoxyphenyl)urea
3-(4-chlorophenyl)-1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
3-(4-chlorophenyl)-1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
3-(4-chlorophenyl)-1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-1-methylurea
(2R,3R,3aS,9bS)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-[2-(3-methoxyphenyl)ethynyl]phenyl]-4-[1-oxo-2-(3-pyridinyl)ethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-[2-(3-methoxyphenyl)ethynyl]phenyl]-4-[1-oxo-2-(3-pyridinyl)ethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(3-oxo-1H-2-benzofuran-1-yl) (2S,5S,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
9-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(pyren-1-ylmethylamino)-1H-purin-6-one
GSK598809
GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pKi of 8.9.
SQLE-IN-1
SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT[1]. SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT[1].